(Q52037855)

20 April 2018

title

Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient. (English)

1 reference

20 April 2018

author name string

Kulick SK

series ordinal

1

1 reference

20 April 2018

Kramer DA

series ordinal

2

1 reference

20 April 2018

language of work or name

English

0 references

publication date

1 March 1993

1 reference

20 April 2018

Annals of Emergency Medicine

published in

1 reference

20 April 2018

volume

22

1 reference

20 April 2018

issue

3

1 reference

20 April 2018

page(s)

610-612

1 reference

20 April 2018

Valproic acid and secondary hyperammonemia

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Hepatotoxicity to sodium valproate: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Valproic acid-induced hyperammonemia in mentally retarded adults

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Hyperammonemia with valproic acid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Fatal Reye-like syndrome associated with valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Reye-like syndrome associated with valproic acid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Valproate-induced hyperammonemia in asymptomatic children.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Valproate-induced hyperammonemia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Sodium valproate associated with phenobarbital: effects on ammonia metabolism in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Chronic valproic acid therapy and incidence of increases in venous plasma ammonia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Effect of associated antiepileptic treatment on valproate-induced hyperammonemia

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Carnitine, valproate, and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Carnitine deficiency and hyperammonemia associated with valproic acid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Protective effect of D,L-carnitine on valproate-induced hyperammonemia and hypoketonemia in primary cultured rat hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

Carnitine deficiency, organic acidemias, and Reye's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2805%2981955-9

7 January 2021

10.1016/S0196-0644(05)81955-9

Identifiers

DOI

1 reference

20 April 2018

1 reference

20 April 2018